Pfizer partners Biocon of India for biosimilar insulin products
This article was originally published in Scrip
Pfizer continues to build on its Indian links in the area of generics, this time for follow-on biologics. It has struck a deal with Biocon, India's largest biotechnology company by revenue, to commercialise Biocon's biosimilar versions of insulin and insulin analogue products – recombinant human insulin, glargine, aspart and lispro - for upfront payments of $200 million and certain additional development, milestone and sales-linked payments.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.